Back

Current control of lipid profile after a contemporary cardiac rehabilitation program: insights from interim analysis of the spanish national ReCardio registry

23 April 2026 (08:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Cardiac rehabilitation programmes: implementation, efficacy and adherence Lipids Delegates Premium Access ESC Preventive Cardiology 2026 European Association of Preventive Cardiology (EAPC)

About the speaker

Photo
Miss Manuela Sestayo Fernandez

Health Research Institute of Santiago de Compostela, Santiago de Compostela (Spain)

5 More presentations in this session

Presentation thumbnail
Current control of patient body composition after a contemporary cardiac rehabilitation program: the ReCardio registry
Miss M. Sestayo Fernandez (Santiago de Compostela, ES)
Abstract Slides
Presentation thumbnail
Physical activity and sedentary behaviour in a phase III cardiac rehabilitation program: identifying vulnerable subgroups
Miss M. Borges (Lisbon, PT)
Abstract Slides
Presentation thumbnail
Cardiac prehabilitation: who declines participation and why? a single-centre analysis of recruitment barriers in the PRECOVERY trial
Ms S. Kaumkoetter (Bad Rothenfelde, DE)
Abstract Slides
Presentation thumbnail
Cardiac rehabilitation in non-ischaemic cardiomyopathies: functional, psychosocial, and structural benefits compared with coronary artery disease
Doctor M. Stiefel (Zurich, CH)
Abstract Slides
Presentation thumbnail
Self-Reported Barriers to Adherence in Cardiac Rehabilitation: A Cross-Sectional Study in Reference Centres
Miss M. Santana E Silva (Recife, BR)
Abstract Slides

Access the full session

Session thumbnail
Cardiac rehabilitation programmes: implementation, efficacy and adherence

The Event

Event poster

ESC Preventive Cardiology 2026

23 April - 25 April 2026
You may be interested in
thumbnail
Webinar
Unmet needs in lipid management: treatment goals and how to achieve them
thumbnail
Congress Presentation
Lipid control in cardiovascular patients
thumbnail
Congress Presentation
Lipidomics to fine-tune cardiovascular risk prediction and personalised treatment

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources